Ms. Langer has served as a director of the Company since March of 2021. Ms. Langer is Chief Business Officer at two stealth biotech companies. Previously, Susan was Founding President of Kojin Therapeutics, a Boston-based start-up focused on developing transformative medicines based on its groundbreaking approach to ferroptosis and cell state biology. Prior to joining Kojin, Susan was Head of Corporate Strategy at Biogen. During her seven years at Biogen, Susan led the strategy and execution of more than a dozen corporate transactions as well as company-wide initiatives, including expanding the neuromuscular and rare disease franchises. She also played an integral role in deal evaluation and portfolio planning for various parts of the business, including multiple sclerosis, gene therapy, dementia and neurocognition, ophthalmology and non-malignant hematology. She received a BA from Cornell University.
March 31 2021